Phase IIa trial of three dosages of fedovapagon in patients with nocturia associated with benign prostatic hyperplasia

Trial Profile

Phase IIa trial of three dosages of fedovapagon in patients with nocturia associated with benign prostatic hyperplasia

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2010

At a glance

  • Drugs Fedovapagon (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms; Nocturia
  • Focus Therapeutic Use
  • Sponsors Vantia Therapeutics
  • Most Recent Events

    • 03 Jun 2010 Results reported at 105th Annual Meeting of the American Urological Association.
    • 29 Jun 2009 Positive results reported in Vantia Therapeutics media release.
    • 24 Mar 2009 Status changed from recruiting to completed, according to a Vantia Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top